Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | OTC | P00480 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13113828 | 0.83 | KDM4E (0.45) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL2324839 | 0.83 | TYMS (0.55) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL13113824 | 0.79 | KDM4E (0.41) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL2064554 | 0.78 | KDM4E (0.53) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL1563641 | 0.77 | PPARD (0.56) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL5968120 | 0.75 | KDM4E (0.50) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL2331836 | 0.75 | KDM4E (0.50) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL1562522 | 0.75 | KDM4E (0.50) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL7825106 | 0.75 | KDM4E (0.50) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL13163283 | 0.74 | KDM4E (0.36) | KDM4EMMP2THRBMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | PHARMASSET, INC. | 2004-12-30 | — | — | US | disclosed |
| EP-1469003-A2 | Tetraphosphonate bicyclic trisanhydrides | Pharmasset, Ltd. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040181078-A1 | Tetraphosphonate bicyclic trisanhydrides | PHARMASSET, LTD. | 2004-09-16 | — | — | US | disclosed |
| US-6713623-B2 | USEFUL AS INTERMEDIATES IN THE SYNTHESIS OF BIOLOGICALLY ACTIVE COMPOUNDS | PHARMASSET, LTD. | 2004-03-30 | — | — | US | disclosed |
| EP-1366055-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | Pharmasset Limited (BB) | 2003-12-03 | — | — | EP | disclosed |
| US-20020161220-A1 | Tetraphosphonate bicyclic trisanhydrides | GILEAD PHARMASSET LLC | 2002-10-31 | — | — | US | disclosed |
| WO-2002048165-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | PHARMASSET LTD. (BB) | 2002-06-20 | — | — | WO | disclosed |
| US-6326490-B1 | ANTIPROLIFERATION AGENTS OR ANTICARCINOGENIC AGENTS | PHARMASSET, LTD. | 2001-12-04 | — | — | US | disclosed |
| EP-0934325-A4 | TETRAPHOSPHONATE BICYCLIC TRISANHYDRIDES | PHARMASSET LTD (US) | 2000-08-16 | — | — | EP | disclosed |
| EP-0934325-A1 | TETRAPHOSPHONATE BICYCLIC TRISANHYDRIDES | Pharmasset, Ltd. (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015563-A1 | TETRAPHOSPHONATE BICYCLIC TRISANHYDRIDES | PHARMASSET, LTD. (US) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181078-A1 | Tetraphosphonate bicyclic trisanhydrides | IDH1, PPIP5K2, DHPS | KDM4E 3656/4885MMP2 1773/4885THRB 3173/4885 |
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | HAVCR2, MAVS, EIF2AK2 | KDM4E 1744/4885MMP2 1043/4885THRB 4722/4885 |
| US-20020161220-A1 | Tetraphosphonate bicyclic trisanhydrides | IDH1, PPIP5K2, DHPS | KDM4E 3656/4885MMP2 1773/4885THRB 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.